conivaptan   Click here for help

GtoPdb Ligand ID: 2203

Synonyms: Vaprisol® | YM-087 | YM087
Approved drug
conivaptan is an approved drug (FDA (2005))
Compound class: Synthetic organic
Comment: Conivaptan is a non-peptide vasopressin receptor antagonist. It antagonises the V1A and V2 receptors but does not inhibit V1B receptor activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 78.09
Molecular weight 498.21
XLogP 6.25
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Cc1[nH]c2c(n1)c1ccccc1N(CC2)C(=O)c1ccc(cc1)NC(=O)c1ccccc1c1ccccc1
Isomeric SMILES Cc1[nH]c2c(n1)c1ccccc1N(CC2)C(=O)c1ccc(cc1)NC(=O)c1ccccc1c1ccccc1
InChI InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
No information available.
Summary of Clinical Use Click here for help
Conivaptan is used to rectify low sodium levels (hyponatremia) and fluid retention caused by conditions associated with elevated vasopressin levels.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Conivaptan is an antagonist of both the arginine vasopressin (AVP) V1A and V2 receptors. AVP is a crucial regulator of water and electrolyte balance. Pharmacologically, antagonism occurs in the renal collecting ducts and results in excretion of free water and lowering of urine osmolality (more salt retained in the plasma, rectifying AVP-induced hyponatremia).